Audit: QRS - Apple Cider Vinegar for Health & Longevity
Audit conducted on 02/09/2026 02:11 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span. Protocol cells trace to ER lines 410/412/414; time-to-effect to ER 465/187; benefits and risks to the ER tier headings (ER 161–243, 267–335); gates to ER 355–384; markers and cadence to the ER table at 495–506 and ER 493; qualitative items to ER 510–514. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No cautious empty-state phrasing carried into the QRS spans; the ER supplies populated content for every span used. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications preserve ER strength (pregnancy/lactation kept in the stop gate, not downgraded to caution); at_a_glance mirrors ER Conclusion strength (“reliably flattens”, “does not grow back”). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | stop_items map 1:1 to the ER “Populations who should avoid” list; caution_items map to the ER interaction bullets; no Benefit- or Risk-Modifying Factor (ER 246–260, 338–350) appears in either gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Attributions are stripped rather than added; e.g. marker_7_why drops the ER’s “the meta-analyses” rather than introducing a source. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Declarative, measured, trade-off-oriented — the same register as the ER Conclusion and Protocol sections. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds throughout, paired with plain-language framing in at_a_glance and the qualitative list. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated impersonally (“Taken immediately before or with the meal”), never as an instruction to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative verbs directed at a reader; the footer disclaimer is the unchanged template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommend”, “advise”, “should”, or equivalent directive phrasing in populated spans. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are load-bearing marker and drug names taken verbatim from the ER (HbA1c, ALT, GLP-1 receptor agonists). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier lines are semicolon-joined heading fragments; gate items are stripped to the key fact; marker rationales are one clause. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-file search for “you”/”your”/”yours”: no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal functional ranges (fasting glucose 75–85 mg/dL, fasting insulin 2–5 µIU/mL) are carried over rather than conventional laboratory ranges. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing, continuous glucose monitoring, annual dental erosion assessment, and DXA are all retained. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The monitoring panel and cadence assume sustained self-directed biomarker tracking, not casual use. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance names the enamel cost and the absence of support for marketplace claims alongside the real glycemic effect, matching the ER’s goal-dependent balance at ER 540. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the header topic uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register maintained (gastroparesis, hypokalemia, erosive esophagitis). The two uses of “blood sugar” are the ER’s own heading wording (ER 169) and the plain-language rendering required by item 7.4 in at_a_glance. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Extracted heading/label sequence from the QRS is byte-identical to the sequence extracted from the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names are present. The extra names are the legitimate expansions of the template’s repeatable rows marker_#name/target/why (10 rows) and qualitative_item# (5 items). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website=”evidence_review”, website=”audit”, website=”full_review”) are present and unchanged at lines 423, 426, 440; the head/style block differs from the template only in the [page_title] substitution. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped to a QRS span is empty; every benefit tier, risk tier, gate, and monitoring row has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3_label are “Standard dose”, “Timing relative to meals”, “Split versus single dose” — verbatim from the ER Protocol bullets at ER 410, 412, 414. Marker names are verbatim from the ER Biomarker column. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels use the ER’s own wording from the Time to effect bullet (ER 465: “post-meal glucose effect”; “Fasting glucose, HbA1c, weight, and lipid changes”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-file search returns no emoji; the ER’s “⚠️ Conflicted” markers on ER 183, 215, 221 were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Single .sheet container with the template’s unmodified A4 print rules; every carried item is condensed to a fragment (tier lines are semicolon-joined headings, marker rationales one clause, gate items stripped of rationale). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the comment opens on line 2 immediately after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3, closing “—” on line 13; the preamble text sits on line 2 before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is duplicated into the header or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring it; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: apple_cider_vinegar_2026-0902-0002_Opus_ER.md, matching the ER frontmatter filename at ER 17. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0902-0150, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: apple_cider_vinegar_2026-0902-0002_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Verified across all nine keys; consistent with 5.4. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Apple Cider Vinegar for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic at ER 8 with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Apple Cider Vinegar for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/02/2026”, the correct reformat of 2026-0902-0150. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” line (ER 30) is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER 536 and ER 540 into effect, timeframe, magnitude, and the enamel cost. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words by whitespace count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Glycemic flattening and the two-to-three-month fasting effect from ER 536; weight/waist/cholesterol from ER 536; enamel wear from ER 540; marketplace claims from ER 536. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “HbA1c” from the ER is rendered as the plain “fasting blood sugar” framing rather than carried through. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Direction only (“shift slightly”); no standardised mean differences or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items map to the “Populations who should avoid Apple Cider Vinegar” list at ER 379–384. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete 1:1 coverage of the six ER avoidance bullets, none added, none dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements at lines 570–587 inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale correctly stripped: ER’s “, including delayed emptying documented on a gastric emptying study” and “, where acid load is poorly buffered” are both removed. No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Retained: “stage 4 or worse (estimated filtration rate below 30 mL/min/1.73 m²)”, “below 3.5 mmol/L”, “grade C or D”, “score 3 or above at any site”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify avoidance populations, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map to the interaction bullets at ER 355–373. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten of the ER’s eleven bullets are carried; the omitted “Other interventions — continuous glucose monitoring and time-restricted eating” bullet is explicitly “Severity: none” (ER 375) and so is not an interaction that changes use. No overlap with the stop gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements at lines 595–609 inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity, Consequence, and Mitigation clauses all stripped; the ER’s in-paren gloss dashes (“— drugs that increase urine output”, “— painkillers that irritate the stomach lining”) are removed, leaving no dash-trailing content. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example drug lists retained: glipizide/glyburide/glimepiride; furosemide/hydrochlorothiazide; semaglutide/tirzepatide/liraglutide; omeprazole/esomeprazole; ibuprofen/naproxen/aspirin; berberine/chromium picolinate/cinnamon/alpha-lipoic acid. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER identifies eleven interaction bullets, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets at ER 410, 412, 414. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, meal timing, and split-versus-single dosing are the three bullets that determine how the intervention is actually taken; the remaining ER bullets are contextual (half-life, competing approaches, genetics, sex, age, baselines). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER’s Therapeutic Protocol section supplies well more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated; e.g. action_1 “15–30 mL daily” / “5% acetic acid, diluted in 200–250 mL water; dose-response flattens above 30 mL” from ER 410. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Post-meal glucose (immediate), fasting glucose and HbA1c (8–12 weeks), and weight and lipids (8–12 weeks) — the full content of the ER’s Time to effect bullet at ER 465. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from the ER’s most reproducible High-tier benefit (postprandial glucose and insulin, ER 165) through the other High-tier benefit (fasting glucose and HbA1c, ER 171) to the Medium-tier weight and the small cholesterol effect (ER 185, 177). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are available and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; time_3_sub “Roughly 1–2 kg over 12 weeks at 30 mL/day” is verbatim from ER 187. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 465), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tier lines are built from the ER Expected Benefits H4 headings at ER 163–243. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 539–560. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of ER heading fragments; no Magnitude figures, provenance notes, or “Net reading” text carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s “(a Common Hormonal and Metabolic Disorder)” on the polycystic ovary syndrome heading (ER 195) is stripped; no parentheses remain in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four tiers (High ER 161, Medium ER 181, Low ER 213, Speculative ER 227), so no sub-section is empty. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tier lines are built from the ER H4 headings at ER 269–335. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 621–642. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Heading fragments only; the ER’s Magnitude lines (e.g. “72.7% (16 of 22)” at ER 293, “18% over eight weeks” at ER 281) are not carried. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s glosses “(upper-abdominal discomfort)”, “(a stomach that empties abnormally slowly)”, “(blood sugar falling too low)” are all stripped; no parentheses remain in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | The ER populates all four tiers (High ER 267, Medium ER 275, Low ER 295, Speculative ER 327), so no sub-section is empty. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets, and rationales all trace to the ER biomarker table at ER 495–506. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows are present: fasting glucose, HbA1c, fasting insulin, serum potassium, ALT, triglycerides, total cholesterol, basic erosive wear examination score, post-meal glucose excursion, bone mineral density T-score. Targets match the ER’s Optimal Functional Range column exactly. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 793–797 reproduce the ER cadence paragraph at ER 493, including the 4-week escalation for insulin, sulfonylurea, digoxin, or diuretic users. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items map to the “Qualitative markers to track alongside the labs” list at ER 510–514. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Complete 1:1 coverage: post-meal energy stability, appetite and inter-meal hunger, reflux/throat burning/dyspepsia, tooth sensitivity, mood and motivation. |
Issues 02/09/2026 02:11
Pass rate 100.00%. No issues found.
Issues 02/09/2026 02:04
- 2.8 / 4.5 — Uncondensed Monitoring and Qualitative prose: The ten Monitoring “Why” cells (lines 667–790) and all five Qualitative Assessment items (lines 811–838) are copied verbatim from ER lines 497–514 at full sentence length, including their trailing em-dash explanations, so neither section was condensed to a per-section budget; combined with the ten wrapping Key Interactions items the sheet is estimated to render at roughly 2.3 A4 pages rather than one.
Fixes 02/09/2026 02:04
- 2.8 / 4.5 — Monitoring “Why” column condensed: All ten
marker_#_whycells were shortened from verbatim ER sentences to compact phrases, e.g. “Detects whether insulin resistance is improving or the glucose fall is being bought with more insulin” to “Separates improving insulin resistance from glucose bought with more insulin”, and “Only for multi-year high-dose users, given the demineralization case report” to “Multi-year high-dose users only”. - 2.8 / 4.5 — Qualitative items trimmed: All five
qualitative_item_#entries had their trailing em-dash explanations condensed, e.g. “Mood and motivation — the depression finding was on self-report scales, so self-report is the appropriate tracker” to “Mood and motivation — the depression finding was on self-report scales”. - 2.8 / 4.5 — Protocol sub-cells and cadence tightened:
action_1_subdropped the redundant “apple cider vinegar”,action_3_subreplaced “returns to baseline” with “clears” (ER line 418), andmonitoring_cadencewas compressed from four to three rendered lines without dropping any of the 8-week, 12-week, 6-month, annual or 4-week-escalation intervals.
Note on residual length: the remaining sheet size is driven by content the checklist mandates be carried in full — all ten biomarkers (14.2), all five qualitative markers (15.2), the preserved example drug lists in Key Interactions (9.5), and the preserved threshold and staging qualifiers in Contraindications (8.5). Further cutting would violate those items, so the condensation was applied only where the checklist permits it.
Issues 02/09/2026 01:57
- 1.3 — Absolute claim replaces scoped claim: [at_a_glance] (line 437) says “Nothing supports the larger marketplace claims”, while the ER Conclusion (line 536) scopes it as “Nothing in the record supports the larger marketplace claims”; dropping “in the record” turns an evidentiary statement into an unqualified absolute one.
Fixes 02/09/2026 01:57
- 1.3 — Restored evidentiary scope in At-A-Glance: Changed “Nothing supports the larger marketplace claims” to “Nothing in the record supports the larger marketplace claims”, matching the ER Conclusion and keeping [at_a_glance] at 59 words.